GANX
vs
S&P 500
GANX
S&P 500
Over the past 12 months, GANX has underperformed S&P 500, delivering a return of +9% compared to the S&P 500's +27% growth.
Stocks Performance
GANX vs S&P 500
Performance Gap
GANX vs S&P 500
Performance By Year
GANX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Gain Therapeutics Inc
Glance View
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. The company is headquartered in Bethesda, Maryland and currently employs 25 full-time employees. The company went IPO on 2021-03-18. The Company, through its subsidiary, GT Gain Therapeutics SA, is a development stage biotechnology company. The firm is focused on developing therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. The company uses its platform, Site-Directed Enzyme Enhancement Therapy (SEE-Tx), to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, potentially treating the underlying disease. Its pipeline includes its Structurally Targeted Allosteric Regulators (STARs), which are small molecules with the potential to treat diseases with unmet medical need. These diseases include Morquio B, GM1 Gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson’s disease, Krabbe disease and Mucopolysaccharidosis type 1.
